MAPT and tauopathy: Antibodies against tau pS396/S40471, 72, 73, 74, 75, 76, 77, 78 were assessed in 13 evaluations and have shown a high degree of success against cognitive and tau‐related endpoints in four MAPT mouse models, but clinical trials in primary tauopathy patients have not been reported.26, 66, 79, 80